Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

被引：39

作者：

Hanauer, Stephen B. ^{[1
]}

机构：

[1] Univ Chicago Hosp, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA

来源：

GUT | 2007年 / 56卷 / 09期

关键词：

D O I：

10.1136/gut.2006.115980

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicify, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

引用

收藏

页码：1181 / 1183

页数：3

相关论文

共 45 条

[1]

Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles [J].

Anderson, PJ .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) :19-22

[2]

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[3]

Predictors of Crohn's disease [J].

Beaugerie, L ;

Seksik, P ;

Nion-Larmurier, I ;

Gendre, JP ;

Cosnes, J .

GASTROENTEROLOGY, 2006, 130 (03) :650-656

[4]

Cohen RD, 2000, AM J GASTROENTEROL, V95, P3469

[5]

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].

Colombel, Jean-Frederic ;

Sandborn, William J. ;

Rutgeerts, Paul ;

Enns, Robert ;

Hanauer, Stephen B. ;

Panaccione, Remo ;

Schreiber, Stefan ;

Byczkowski, Dan ;

Li, Ju ;

Kent, Jeffrey D. ;

Pollack, Paul F. .

GASTROENTEROLOGY, 2007, 132 (01) :52-65

[6]

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease [J].

Corken Mackey, Ann ;

Green, Lanh ;

Liang, Li-ching ;

Dinndorf, Patricia ;

Avigan, Mark .

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2007, 44 (02) :265-267

[7]

D'Haens GR, 2006, GASTROENTEROLOGY, V130, pA110

[8]

Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine [J].

Dayharsh, GA ;

Loftus, EV ;

Sandborn, WJ ;

Tremaine, WJ ;

Zinsmeister, AR ;

Witzig, TE ;

Macon, WR ;

Burgart, LJ .

GASTROENTEROLOGY, 2002, 122 (01) :72-77

[9]

Review article: thiopurines in inflammatory bowel disease [J].

Derijks, L. J. J. ;

Gilissen, L. P. L. ;

Hooymans, P. M. ;

Hommes, D. W. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (05) :715-729

[10]

Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics [J].

Ekstrom Smedby, Karin ;

Baecklund, Eva ;

Askling, Johan .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (11) :2069-2077

← 1 2 3 4 5 →